Scripps Florida Scientists Make Strides in erapy Preventing Addiction Relapse by Erasing Drug-Aociated Memories

Scripps Florida Scientists Make Strides in Therapy Preventing Addiction Relapse by Erasing Drug-Associated Memories Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models

JUPITER, FL, August 4, 2015 Recovering addicts often grapple with the ghosts of their addiction memories that tempt them to relapse even after rehabilitation and months, or even years, of drug-free living. Now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have made a discovery that brings them closer to a new therapy based on selectively erasing these dangerous and tenacious drug-associated memories.

We now have a viable target and by blocking that target, we can disrupt, and potentially erase, drug memories, leaving other memories intact, said TSRI Associate Professor Courtney Miller. The hope is that, when combined with traditional rehabilitation and abstinence therapies, we can reduce or eliminate relapse for meth users after a single treatment by taking away the power of an individual's triggers.

The new study, published this week online ahead of print by the journal Molecular Psychiatry, demonstrates the effectiveness of a single injection of an early drug candidate called blebbistatin in preventing relapse in animal models of methamphetamine addiction.

The new study builds on previous work in Miller's lab. In 2013, the team made the surprising discovery that drug-associated memories could be selectively erased by targeting actin, the protein that provides the structural scaffold supporting memories in the brain. However, the therapeutic potential of the finding seemed limited by the problem that actin is critically important throughout the body taking a pill that generally inhibits actin, even once, would likely be fatal.

In the new study, Miller and her colleagues report a major advance the discovery of a safe route to selectively targeting brain actin through nonmuscle myosin II (NMII), a molecular motor that supports memory formation. To accomplish this, the research used a compound called blebbistatin that acts on this protein.

The results showed that a single injection of blebbistatin successfully disrupted long-term storage of drug-related memories and blocked relapse for at least a month in animal models of methamphetamine addiction.

What makes myosin II such an exciting therapeutic target is that a single injection of blebbistatin makes methamphetamine-associated memories go away, along with dendritic spines, the structures in the brain that store memory, said Research Associate Erica Young, a member of the Miller lab and a key author of the new study, along with Research Associates Ashley M. Blouin and Sherri B. Briggs.

Blouin added, Drugs targeting actin usually have to be delivered directly into the brain. But blebbistatin reaches the brain even when injected into the body's periphery and, importantly, the animals remained healthy.

Moreover, the effect of this novel treatment approach was specific to drug-associated memories (not affecting other memories), and the animals were still able to form new recollections.

Our results argue for developing small molecule inhibitors of nonmuscle myosin II as potential therapeutics for relapse prevention, and that's exactly what we're doing with our colleagues here at Scripps with expertise in drug development, said Briggs.

In addition to Miller, Young, Blouin and Briggs, other authors of the study, Nonmuscle Myosin IIB as a Therapeutic Target for the Prevention of Relapse to Methamphetamine Use, include Stephanie E. Sillivan, Michael D. Cameron and Gavin Rumbaugh of TSRI.

This work was supported by the National Institute on Drug Abuse (R01DA034116, R01DA034116S1 and R21DA036376), the National Institute for Neurological Disorders and Stroke (R01NS064079), the National Institute for Mental Health (R01MH096847) and the Brain and Behavior Research Foundation (NARSAD Young Investigator Awards).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:

Office of Communications

Tel: 858-784-2666

Fax: 858-784-8136

press@scripps.edu

LINK:	http://www.scripps.edu/news/press/2015/20150804miller.html...
	See more stories from scripps

Most recent headlines